PPT-Optimal Timing of Hepatitis C Treatment for Patients on the

Jagpreet Chhatwal PhD 12 Sumeyye Samur PhD 12 Brian Kues MS 3 Turgay Ayer PhD 3 Mark S Roberts MD MPP 3 Fasiha Kanwal MD MSHS 56 Chin Hur MD 12. Gilead Sciences Inc. (GILD). Presented by: . Sudharshan. . Mohanram. , . Frank Han. Investment Thesis. Why is stock ‘undervalued’?. Overreaction: Gilead Sciences.  reported disappointing . results on its . thalassaemia. . Where . are we now?. Telaprevir . and . boceprevir. harbingers . of important . treatment advance. Improved response rates . observed : . naive . and . experienced patients. SVR > 70. Developed by Camilla S. Graham, MD, BIDMC, 5/5/15. . cgraham@bidmc.harvard.edu. . . Slides can be selected or altered as needed.. Disclosures. 75% of People with Hepatitis C in the US are Baby Boomers. Dr. Joanna Eveland, MS, MD. Clinical Chief for Special Populations, MNHC. O. bjectives. Understand recommendations for age cohort and risk based screening for Hepatitis C. Review strategies for health promotion and optimizing treatment readiness for HCV infected homeless individuals. Sameh W. Boktor, MD, MPH. Medical Epidemiologist. Pennsylvania Department of Health. Harrisburg, Pennsylvania. Disclosures. Off-label and/or investigational use of pharmaceuticals may be discussed in the presentation. This disclosure is to ensure participants in the activity may formulate their own judgments regarding the presentation.. . -Stacey . Trooskin. MD, PhD, Drexel University & . HepCAP. . -Karen Arendt, RN, St. Joseph's Center for Liver & Hepatobiliary Disease. -Courtney Jones, Patient Advocate Foundation. www.nvhr.org/program. Nojan. PGY-2 . April 2016 . Objectives . Understand the . diagnostic . w. orkup . for Alcoholic Hepatitis . Review risk stratification . algorithms. Review . management . and discharge considerations for alcoholic hepatitis . ASSOC. PROF. DR. INGRID MIRON. What is Viral Hepatitis ?. . Viral hepatitis is a systemic disease with primary inflammation of the liver by any one of a . heterogenous. group of . hepatotropic. viruses. Sameh W. Boktor, MD, MPH. Medical Epidemiologist. Pennsylvania Department of Health. Harrisburg, Pennsylvania. Disclosures. Off-label and/or investigational use of pharmaceuticals may be discussed in the presentation. This disclosure is to ensure participants in the activity may formulate their own judgments regarding the presentation.. Control Program in . Haryana.. 1. Rajeev Arora, IAS . Additional Chief Secretary,. Health Department,. Government of Haryana,. Chandigarh. Phone: 0172-2706481. Amneet. P. Kumar, IAS. Mission Director, . About these slides. These slides provide highlights of new data presented at the International Liver Congress 2019. Please feel free to use, adapt, and share these slides for your own personal use; however, please acknowledge EASL as the source. National Guidelines for Diagnosis & Management of Viral Hepatitis National Guidelines for PrefaceViral hepatitis is increasingly being recognized as a public health problem in India. While hepatitis A PARTNERSHIP TOWARDS ELIMINATION OF A MAJOR PUBLIC HEALTH THREAT BY 2030. Wifi. : . Welcome. Hugh Morris, Chair, London Drug and Alcohol Policy Forum. . Introduction: How we can work together to achieve elimination. Jocelyn James, MD. Assistant Professor, Department of Medicine. University of Washington. . Adapted from slides developed in collaboration with Judith . Tsui. and the Washington State Department of Health.